Financial Performance - The company's revenue for Q1 2023 was CNY 805,928,136.64, representing a 23.11% increase compared to CNY 654,635,799.08 in the same period last year[19] - The net profit attributable to shareholders for Q1 2023 was CNY 170,317,490.97, a 64.47% increase from CNY 103,554,147.18 year-on-year[19] - The total profit amounted to 205,802,789.13, an increase from 125,762,971.64[45] - Net profit reached 174,373,215.65, compared to 106,852,356.15 in the previous period, reflecting a significant growth[45] - The net profit attributable to the parent company's owners was 170,317,490.97, up from 103,554,147.18[45] - The overall financial performance indicates a robust growth trajectory and improved profitability metrics[45] Cash Flow - The net cash flow from operating activities surged to CNY 222,678,836.22, marking a significant increase of 905.46% compared to CNY 22,146,972.56 in the previous year[19] - Cash received from sales and services increased by 30.39% to 782,399,226.54, primarily due to increased collections[32] - Cash paid for purchasing goods and services rose by 32.06% to 295,808,934.54, mainly due to increased procurement of medical supplies[32] - Investment activities generated a net cash outflow of ¥20,268,839.68, an improvement from a net outflow of ¥712,158,654.56 in the previous period[41] - The company reported a net increase in cash and cash equivalents of ¥179,436,811.37, contrasting with a decrease of ¥690,691,299.91 in the previous period[41] Assets and Liabilities - The total assets at the end of Q1 2023 amounted to CNY 8,196,383,781.60, reflecting a 2.03% increase from CNY 8,033,175,408.45 at the end of the previous year[19] - The total current assets reached CNY 6,239,082,168.98, an increase from CNY 6,073,386,246.99 at the beginning of the year[15] - Total liabilities rose to ¥771,236,715.69 from ¥748,348,858.19 in the previous period, reflecting ongoing financial commitments[43] - The total equity attributable to shareholders increased to ¥7,355,951,977.81, up from ¥7,185,634,486.84 in the previous period, indicating growth in shareholder value[43] Earnings and Expenses - The basic earnings per share for Q1 2023 was CNY 0.34, a 61.90% increase from CNY 0.21 in the same period last year[19] - The diluted earnings per share also stood at CNY 0.34, reflecting the same growth rate of 61.90% compared to CNY 0.21 year-on-year[19] - Operating costs increased by 42.64% to 424,061,104.31, attributed to revenue growth and changes in sales structure[23] - R&D expenses rose by 45.32% to 9,984,394.66, driven by increased investment in blood product research[23] - Income tax expenses were 31,429,573.48, up from 18,910,615.49, indicating higher tax obligations[45] Other Financial Metrics - The company reported a significant increase in non-recurring gains and losses amounting to CNY 32,502,159.86 after tax for the current period[22] - Accounts receivable decreased by 100.00% to 0.00, primarily due to the expiration of commercial acceptance bills[23] - Prepayments decreased by 33.84% to 6,389,963.81, mainly due to the write-off of prepayments for goods received[23] - Fair value changes in investment income surged by 518.81% to 34,757,152.48, resulting from changes in the fair value of financial products and merger fund investments[23] - The company reported a significant increase in net profit from continuing operations, maintaining a strong performance[45]

Group 1: Financial Performance - The company's Q1 2023 performance showed significant growth in net profit from blood products, primarily due to increased sales of immunoglobulin, PCC, and anti-hemophilic factors compared to the same period last year [2] - Non-blood product business, particularly the distribution of recombinant drugs, also saw a substantial increase in net profit, driven by higher sales volumes of immunoglobulin and albumin products [3] Group 2: Profitability and Production Efficiency - The company maintains a leading position in the industry regarding tonnage profit margins, attributed to high product yield rates, balanced product structure, and effective production-sales coordination [3] - Measures to enhance tonnage profit include accelerating R&D, optimizing production processes, and increasing market share through academic promotion [3] Group 3: Inventory and Market Strategy - The inventory levels for key products such as immunoglobulin and albumin remain low, with the company aiming for a 5% market share for factor VIII by the end of 2023 [3] - The marketing management system has been significantly optimized since 2018, resulting in competitive advantages in market penetration and collection rates [3] Group 4: Plasma Collection and Future Plans - The company plans to collect 650-700 tons of plasma per year by 2025, leveraging existing plasma stations and establishing new ones [4] - New plasma stations typically achieve a collection volume of 8-10 tons in the first year, reaching 30 tons within approximately three years [4] Group 5: R&D and Product Development - Ongoing R&D projects include human von Willebrand factor and high-concentration immunoglobulin, with clinical trial applications approved in 2021 [4] - The company aims to broaden its product line and enhance competitiveness with the launch of new products by 2027 [4] Group 6: Mergers and Acquisitions - The company is focused on divesting non-blood product businesses to eliminate competition, with plans to complete the transfer of Tianan Pharmaceutical and Guangdong Fuda by the end of 2023 [5] - Future M&A strategies will concentrate on blood product businesses to achieve growth and enhance market position [6] Group 7: Internationalization Strategy - The company has a clear internationalization strategy, aiming to expand its foreign trade and explore overseas partnerships for technology and product collaboration [6] - The strategy includes registering products in countries with recognized drug regulatory systems and gradually entering stricter markets like Europe and the US [6]

Financial Performance - The company’s operating revenue for 2022 was ¥2,758,701,315.10, representing a 4.08% increase compared to ¥2,650,528,421.87 in 2021[17]. - The net profit attributable to shareholders for 2022 was ¥432,197,553.97, a 25.45% increase from ¥344,528,999.52 in 2021[17]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥392,124,538.69, up 33.61% from ¥293,492,852.21 in 2021[17]. - The company's cash flow from operating activities decreased by 55.67% to ¥596,437,198.85 in 2022, down from ¥1,345,377,085.21 in 2021[17]. - The total assets at the end of 2022 were ¥8,033,175,408.45, a 5.40% increase from ¥7,621,775,902.48 at the end of 2021[17]. - The net assets attributable to shareholders at the end of 2022 were ¥7,185,634,486.84, reflecting a 5.22% increase from ¥6,829,074,243.57 at the end of 2021[17]. - The company achieved total operating revenue of ¥2,758,701,315.10, a year-on-year increase of 4.08%[45]. - The operating profit reached ¥532,180,673.01, reflecting a growth of 20.12% compared to the previous year[45]. - The blood products business generated operating revenue of ¥1,342,217,158.74, up 8.96% from ¥1,231,862,874.38 in 2021[46]. - The diabetes business saw a decline in operating revenue to ¥178,390,600.88, down 25.01% due to the impact of centralized procurement policies[46]. - The biopharmaceutical business reported operating revenue of ¥438,116,868.80, a decrease of 14.25% influenced by product exits from medical insurance[47]. - The pharmaceutical distribution business (Fuda Pharmaceutical) achieved operating revenue of ¥814,214,548.78, an increase of 22.69% driven by increased sales of immunoglobulin products[47]. Dividend Distribution - The company plans to distribute a cash dividend of 2 RMB per 10 shares to all shareholders, based on a total of 504,248,738 shares[4]. - The company plans to distribute a cash dividend of 1.5 yuan per 10 shares, totaling 75,637,310.70 yuan (including tax) based on a share base of 504,248,738 shares[162]. - The total cash dividend amount for the year is 100,849,747.60 yuan (including tax), which accounts for 100% of the total profit distribution[164]. - The company reported a distributable profit of 2,086,809,493.36 yuan for the year[164]. - The company has not proposed any stock bonus distribution for the reporting period[165]. Market and Product Development - The company reported a total of 9 product varieties in the blood products sector, with a significant market demand exceeding the current supply[26]. - The domestic market for blood products reached ¥43 billion in 2021, with a year-on-year growth of 11.17%[28]. - The estimated demand for raw plasma in China has exceeded 16,000 tons per year, while the actual collection was approximately 10,181 tons in 2022, indicating a supply shortfall[28]. - The company focuses on blood products, including albumin, immunoglobulin, and coagulation factors, and is one of the leading domestic producers in this sector, offering 9 product varieties in 23 specifications[33]. - The company aims to become a world-class blood product enterprise while stabilizing its non-blood product business, emphasizing the importance of blood products in its overall strategy[33]. - The company has increased R&D investment to enhance its product pipeline, being one of the few in the industry with a complete range of three types of products[29]. - The company has optimized its product structure with the recent launch of PCC and factor VIII, improving its core product yield above the industry average[29]. - The company has achieved a balance between production and sales for its core products, enhancing its market penetration and coverage through academic system development[29]. - The company aims to expand its market presence and enhance product competitiveness through new strategies and product development[35]. - The company launched new products, including the production approval of coagulation factor VIII, enhancing its product portfolio[50]. Research and Development - The company has a strong R&D capability, having undertaken over 20 government projects and holding more than 200 patents, with ongoing projects aimed at expanding its blood product offerings[58]. - The number of R&D personnel increased to 220 in 2022, a growth of 2.33% compared to 215 in 2021[78]. - R&D expenditure amounted to ¥77,174,985.45 in 2022, representing 2.80% of operating revenue, down from 3.39% in 2021[78]. - The company is currently conducting clinical research on several products, including the von Willebrand factor and intravenous immunoglobulin, with significant development expenditures reported[78]. - The company has committed to returning all temporarily used idle funds to the dedicated fundraising account by the end of the specified period[100]. Operational Challenges and Strategies - The company experienced a significant decline in cash flow from operating activities, which may impact future investment and operational strategies[17]. - The company faces risks in new product development due to long cycles and high costs; it will conduct comprehensive market research and strengthen project management to ensure timely product launches[117]. - The company is adapting to increasing regulatory pressures in the pharmaceutical industry by optimizing production capacity and enhancing product pipelines to counter potential price declines[119]. - The company is committed to enhancing its operational management capabilities at plasma stations, focusing on cost control and quality management to increase plasma collection volume[109]. - The company plans to implement a series of operational optimization measures to achieve steady growth in revenue and net profit in 2023[112]. Environmental Compliance - The company has successfully passed environmental protection inspections and complies with national emission standards, ensuring no pollution to surrounding environments[175]. - The company’s COD discharge is 83.518 mg/L, well below the industry standard of 220 mg/L, with a total discharge of 4.227 tons[178]. - The company reported a total nitrogen level of 5.898 mg/L at the North Corner facility, which is below the regulatory limit of 40 mg/L[179]. - The company achieved a liquid waste discharge of 3.8905 tons, adhering to the wastewater discharge standards[179]. - The company has implemented online monitoring for wastewater parameters to ensure compliance with environmental standards[179]. Corporate Governance - The company has established a fair, transparent, and effective performance evaluation and incentive mechanism for senior management, aiming to attract and retain outstanding talent[129]. - The company maintains complete independence in business, personnel, assets, organization, and finance from its controlling shareholders, ensuring independent operations[131][132][133][134][135]. - The company has a dedicated board secretary responsible for information disclosure, ensuring timely and accurate communication with shareholders[129]. - The company has set up three specialized committees under the board of directors to enhance operational efficiency[129]. - The company held its annual general meeting with a participation ratio of 42.97% on April 12, 2022, and a temporary shareholders' meeting with a participation ratio of 46.31% on January 28, 2022[137].

博雅生物投资者关系活动记录表 证券代码：300294 证券简称：博雅生物 博雅生物制药集团股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|--------------------------|--------------------------------------------------------| | | □ | 特定对象调研 □分析师会议 | | 投资者关系 | □ 媒体采访 □业绩说明会 | | | 活动类别 | □ 新闻发布会 □路演活动 | | | | √ 电话会议 | | | 参与单位名称及 | 详见附件：人员名单 | | | 人员姓名 | | | | 时 间 | 2020 年 03 月 26 | 日 15： 30-16：30 | | 地 点 | 不适用 | | | 上市公司接待 人员姓名 | 董事会秘书范一沁 | | | 投资者关系活动 | | 本次投资者关系活动主要内容如下： | | 主要内容介绍 | 1 | 、疫情之后整体静丙的学术推广会有什么变化吗？ | | | | 答：会有一定的变化，但是各个厂家的策略肯定 ...

Group 1: Impact of COVID-19 on Company Operations - The COVID-19 pandemic has significantly affected China's public health sector, leading to increased awareness of new pneumonia and rational drug use [2] - The company discussed its products' roles in treating severe patients, including the use of immunoglobulin and albumin for symptomatic treatment [3][4] - The pandemic is expected to enhance long-term recognition of blood products and their emergency use in clinical settings [3] Group 2: Plasma Collection and Inventory Management - The industry plasma collection volume was 9,200 tons, with recovery dependent on the lifting of gathering restrictions and the reduction of the infection coefficient to 0.4 [4] - The company has paused plasma collection to control the infection source, maintaining a two-month supply of inventory [4][5] - The company’s inventory of qualified plasma in Guangdong is approximately 800 tons, with a production timeline of about four months [7] Group 3: Demand and Usage of Immunoglobulin - The average usage of immunoglobulin in China is less than 1/10 compared to developed countries, indicating a lack of awareness [5] - In January 2020, the national usage of immunoglobulin was around 2 million doses, with a total demand in 2019 of approximately 13 million doses [5][6] - The treatment guidelines suggest a dosage of 0.25 grams of immunoglobulin per kilogram of body weight, with a typical patient requiring around 30 doses [6] Group 4: Pricing and Market Dynamics - The prices of immunoglobulin and albumin are expected to rise due to increased demand and limited supply, although the company will not raise prices during the pandemic [6][8] - The government is implementing policies to support the production of essential products during the pandemic, which may shorten the approval process for product releases [8] Group 5: Financial Performance Expectations - The company anticipates a year-on-year revenue growth of 5.00% to 25.00% for the first quarter, based on current conditions and previous year data [6][7] - The impact of the pandemic on the company's performance is expected to be minimal, with ongoing production in Guangdong being closely monitored by government officials [7]

Group 1: Impact of COVID-19 on Blood Products - The COVID-19 pandemic poses a significant challenge to public health and has a major impact on the national economy, while also promoting the healthcare and wellness industry [1] - There is a substantial increase in the awareness and usage of immunoglobulin (IVIG) among healthcare workers aiding Wuhan, with most having received IVIG injections for COVID-19 prevention [3] - The pandemic is expected to lead to a long-term increase in the recognition of blood products, significantly enhancing their importance in the healthcare sector [3] Group 2: Supply and Demand Dynamics - As of the end of January 2020, the national inventory of IVIG was approximately 1.8 million bottles, with a significant consumption rate during the pandemic [3] - The total plasma collection in the industry was around 9,200 tons in 2019, but collection has been suspended due to the pandemic, with expectations of a year-on-year decline in 2020 [4] - The company is closely monitoring the pandemic situation to prepare for resuming plasma collection once conditions are favorable [4] Group 3: Pricing and Market Trends - Currently, there are two pricing structures: terminal price and factory price, with no adjustments made to terminal prices during the pandemic [6] - It is anticipated that prices will rise in the post-pandemic era due to supply-demand dynamics [6] - Long-term prospects for plasma collection are positive, with the potential for increased collection volumes as public awareness of blood products grows [6] Group 4: Company Operations and Future Plans - The company resumed production at its Guangdong facility in August 2019, with over 12,000 bottles of albumin sent to Wuhan by the end of 2019 [5] - The company is in the process of acquiring Luoyisheng Biotechnology, with the matter currently under review by the China Securities Regulatory Commission [6] - The company has invested significantly in R&D, with plans to submit applications for new products in the future [7]

Group 1: Market Impact and Pricing - In Q2 2020, the industry experienced price increases for certain products due to the impact of the pandemic, leading to questions about potential adjustments in product ex-factory prices [2] - The company reported stable ex-factory prices despite overall supply-demand tension in the market [3] - The average collection volume for single plasma stations in China is approximately 35 tons [3] Group 2: Production and Supply Expectations - The total plasma collection volume in 2019 was 370 tons, with expectations for a slight decrease in 2020 due to the pandemic [3] - The company will dynamically adjust its plasma supply based on collection conditions [3] - The maturation period for new plasma stations is typically 3-5 years, after which collection volumes stabilize [4] Group 3: Future Product Trends - The demand for products is expected to rise due to factors such as domestic medical advancements, market demand, and an aging population [4] - The introduction of import policies for albumin has not significantly impacted domestic products, with imports accounting for 50-60% of the market [4] Group 4: Research and Development - The company has submitted applications for PCC and factor VIII, with expected approvals within the year and by the end of next year, respectively [4] - There is ongoing work to supplement clinical data for factor VIII, with approval timelines subject to uncertainty [4] Group 5: Sales and Marketing Strategies - The increase in sales expenses is viewed as a normal strategic adjustment within the industry, reflecting a shift towards direct sales channels [4] - The company has made significant investments in academic promotion and market services in recent years [4] Group 6: Plasma Procurement Progress - The company is actively pursuing plasma procurement in Guangdong, with no definitive approvals yet, but will announce updates as they occur [5]